Journal of medicinal and pharmaceutical chemistry 2015-07-01

Structural evolutions of salicylaldoximes as selective agonists for estrogen receptor beta.

E M Balboa, Y-X Li, B-N Ahn, S-H Eom, H Domínguez, C Jiménez, J Rodríguez

Index: J. Med. Chem. 52 , 858-67, (2009)

Full Text: HTML

Abstract

The bioisosteric replacement of the phenol ring, a signature functional group of most estrogen receptor (ER) ligands, with a hydrogen-bonded pseudocyclic ring, led to the development of a novel class of nonsteroidal ER-ligands based on a salicylaldoxime template. A series of structural modifications were applied to selected molecules belonging to the monoaryl-salicylaldoxime chemical class in an attempt to improve further their ERbeta-selective receptor affinity and agonist properties. Among several modifications, the best results were obtained by the simultaneous introduction of a meta-fluorine atom into the para-hydroxyphenyl substituent present in the 4-position of salicylaldoxime, together with the insertion of a chloro group in the 3-position of the central scaffold. The resulting compound showed the best affinity (K(i) = 7.1 nM) and selectivity for ERbeta over ERalpha. Moreover, in transcription assays, it proved to be a selective and potent ERbeta-full agonist with an EC(50) of 4.8 nM.


Related Compounds

Related Articles:

Inducible, tightly regulated and growth condition-independent transcription factor in Saccharomyces cerevisiae.

2014-01-01

[Nucleic Acids Res. 42(17) , e130, (2014)]

A precisely substituted benzopyran targets androgen refractory prostate cancer cells through selective modulation of estrogen receptors.

2015-03-15

[Toxicol. Appl. Pharmacol. 283(3) , 187-97, (2015)]

Alpha-fetoprotein, identified as a novel marker for the antioxidant effect of placental extract, exhibits synergistic antioxidant activity in the presence of estradiol.

2014-01-01

[PLoS ONE 9(6) , e99421, (2014)]

Selective inhibition of RET mediated cell proliferation in vitro by the kinase inhibitor SPP86.

2014-01-01

[BMC Cancer 14 , 853, (2014)]

Loss of TGFβ Receptor Type 2 Expression Impairs Estrogen Response and Confers Tamoxifen Resistance.

2015-04-01

[Cancer Res. 75(7) , 1457-69, (2015)]

More Articles...